Ilze Konrade

Ilze Konrade

Auto-generated profile, based on publicly available information

Ilze Konrade

Translational Omics group

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MBMonta Briviba
Monta Briviba
LALaura Ansone
Laura Ansone
ISIvars Silamikelis
Ivars Silamikelis
VRVita Rovite
Vita Rovite
IEIlze Elbere
Ilze Elbere
MUMonta Ustinova
Monta Ustinova
Metformin, a biguanide agent, is the first-line treatment for type 2 diabetes mellitus due to its glucose-lowering effect. Despite its wide application in the treatment of multiple health conditions, the glycemic response to metformin is highly variable, emphasizing the need for reliable biomarkers. We chose the RNA-Seq-based comparative transcriptomics approach to evaluate the systemic effect of metformin and highlight potential predictive biomarkers of metformin response in drug-naïve volunteers with type 2 diabetes in vivo. The longitudinal blood-derived transcriptome analysis revealed metformin-induced differential expression of novel and previously described genes involved in cholesterol homeostasis (SLC46A1 and LRP1), cancer development (CYP1B1, STAB1, CCR2, TMEM176B), and immune responses (CD14, CD163) after administration of metformin for three months. We demonstrate for the first time a transcriptome-based molecular discrimination between metformin responders (delta HbA1c ≥ 1% or 12.6 mmol/mol) and non-responders (delta HbA1c < 1% or 12.6 mmol/mol), that is determined by expression levels of 56 genes, explaining 13.9% of the variance in the therapeutic efficacy of the drug. Moreover, we found a significant upregulation of IRS2 gene (log2FC 0.89) in responders compared to non-responders before the use of metformin. Finally, we provide evidence for the mitochondrial respiratory complex I as one of the factors related to the high variability of the therapeutic response to metformin in patients with type 2 diabetes mellitus.

1 December 2019 in Sleep Medicine
Verified
Journal Article
Closed access
IKI. Kalere
I. Kalere
IKI. Konrade
I. Konrade
APAnna Proskurina
Anna Proskurina
SUSabīne Upmale-Engela
Sabīne Upmale-Engela
TZT. Zake
T. Zake
Peteris TretjakovsPeteris Tretjakovs
Peteris Tretjakovs

1 April 2025 in Gut Microbes Reports
Verified
Journal Article
Open access
MRMaija Rozenberga
Maija Rozenberga
RSRihards Saksis
Rihards Saksis
IEIlze Elbere
Ilze Elbere
LBLīga Birzniece
Līga Birzniece
MBMonta VAT No: Brīvība
Monta VAT No: Brīvība
JKJanis Klovins
Janis Klovins
Different microbial communities are found almost everywhere in and on the human body. However, commensal microbiome research is mainly focused on key sites such as the gut, skin, mouth, and vagina,...

15 November 2023 in General Surgery
Verified
Journal Article
Open access
PDF file
EBE. Bobrovs
E. Bobrovs
JPJānis Pāvulāns
Jānis Pāvulāns
IKI. Konrade
I. Konrade
RLR. Laguns
R. Laguns
Haralds PlaudisHaralds Plaudis
Haralds Plaudis
Insulinoma is a type of neuroendocrine tumour with an incidence of 1—4 cases per million. Multiple insulinomas constitute less than 10% of all insulinomas. Surgery is the treatment of choice for insulinoma. The operation can be done with an open or laparoscopic approach, with cure rates ranging from 77% to 100%. Pancreatic resection is recommended for tumours larger than 2 cm in size, while enucleation is advised for lesions smaller than 2cm if the tumour is at least 2—3 mm away from the main pancreatic duct to prevent the formation of a fistula. For better intraoperative localization of lesions, bimanual palpation together with intraoperative ultrasonography (IOUS) is advised. Palpation alone has 70% sensitivity, but together with IOUS, it reaches 85—95% A young female patient in her late 20s with non‑specific complaints and a medical history of epilepsy dating back to the age of 17 underwent a physical examination. Blood test results indicated severe hypoglycemia, and magnetic resonance imaging (MRI) revealed an 11‑mm neoplasia in the body of the pancreas. A 72‑hour fasting test confirmed the diagnosis of insulinoma, and the patient underwent laparoscopic surgery. IOUS was done for the precise localization of the lesion, and another tumour in the pancreatic tail was found. A spleen‑preserving laparoscopic distal pancreatectomy was performed. Histologic reports confirmed multifocal Grade 1 insulinoma. The postoperative course was uneventful. After 4 months of follow‑up, computed tomography (CT) was done, and there were no signs of recurrence of insulinoma, pancreatic pseudocysts, or other signs of postoperative complications. Since the operation, the patient has not had any episodes of hypoglycemia or seizures. The wide spectrum of symptoms, which are not specific to insulinomas, in particular seizures, can make it difficult to establish a correct diagnosis and can be mistaken for other psychiatric or neurologic disorders. This case clearly shows the advantages of IOUS‑guided surgery in achieving better visualization and outcomes. After enucleation of the smaller lesion without the use of IOUS, other insulinomas would be missed and left in place because they were located deeply in the parenchyma. Simple visualization and palpation would not be enough.